Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP4K3 | Q8IVH8 | 12/20 | 0.68 |
| ▸ | MERTK | Q12866 | 4/20 | 0.58 |
| ▸ | AXL | P30530 | 3/20 | 0.58 |
| ▸ | MET | P08581 | 2/20 | 0.58 |
| ▸ | TYRO3 | Q06418 | 1/20 | 0.58 |
| ▸ | JAK2 | O60674 | 2/20 | 0.56 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2386302 | 0.87 | MERTK (0.59) | MAP4K3MERTKAXLMETTYRO3 | |
| SCHEMBL18611194 | 0.87 | MAP4K3 (0.70) | MAP4K3MERTKAXLMETTYRO3 | |
| SCHEMBL2385504 | 0.84 | MET (0.53) | MAP4K3MERTKAXLMET | |
| SCHEMBL21779416 | 0.82 | MAP4K3 (0.70) | MAP4K3MERTKAXLMETTYRO3 | |
| SCHEMBL26151261 | 0.81 | MAP4K3 (0.74) | MAP4K3JAK2 | |
| SCHEMBL3954315 | 0.81 | AXL (0.58) | MAP4K3MERTKAXLTYRO3JAK2 | |
| SCHEMBL18637099 | 0.79 | MAP4K3 (0.64) | MAP4K3METJAK2NTRK1 | |
| SCHEMBL18591563 | 0.79 | IKBKE (0.62) | MERTKAXLMET | |
| SCHEMBL6726838 | 0.77 | MAP4K3 (0.64) | MAP4K3METJAK2NTRK1 | |
| SCHEMBL18616304 | 0.77 | MAP4K3 (0.60) | MAP4K3METJAK2NTRK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8017611-B2 | Pyridine and pyrazine derivatives -083 | ASTRAZENECA AB (SE) | 2011-09-13 | — | — | US | disclosed |
| EP-2215085-B1 | PYRIDINE AND PYRAZINE DERIVATIVES USEFUL IN THE TREATMENT OF CELL PROLIFERATIVE DISORDERS | ASTRAZENECA AB (SE) | 2011-09-07 | — | — | EP | disclosed |
| EP-2215085-A2 | PYRIDINE AND PYRAZINE DERIVATIVES USEFUL IN THE TREATMENT OF CELL PROLIFERATIVE DISORDERS | AstraZeneca AB (SE) | 2010-08-11 | — | — | EP | disclosed |
| US-20090118305-A1 | PYRIDINE AND PYRAZINE DERIVATIVES - 083 | ASTRAZENECA AB (SE) | 2009-05-07 | — | — | US | disclosed |
| WO-2009053737-A2 | PYRIDINE AND PYRAZINE DERIVATIVES USEFUL IN THE TREATMENT OF CELL PROLIFERATIVE DISORDERS | ASTRAZENECA AB (SE) | 2009-04-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090118305-A1 | PYRIDINE AND PYRAZINE DERIVATIVES - 083 | MKI67, CCND3, CCND1 | MAP4K3 102/4885MERTK 3823/4885AXL 2302/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.